Sofgen Pharma S.A. (PROCF)

Market Cap	55.75M -83.0%
Revenue (ttm)	423.75M +5.1%
Net Income	40.34M +11.7%
EPS	0.40 +11.8%
Shares Out	2.30B
PE Ratio	0.06
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	232
Average Volume	1,106
Open	0.0242
Previous Close	0.0251
Day's Range	0.0242 - 0.0242
52-Week Range	0.0101 - 1.5000
Beta	63.09
RSI	46.58
Earnings Date	May 15, 2026

About Sofgen Pharma

Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision car...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1977
• Employees: 5,000
• Stock Exchange: OTCMKTS
• Ticker Symbol: PROCF

Financial Performance

In 2023, Sofgen Pharma's revenue was $423.75 million, an increase of 5.10% compared to the previous year's $403.20 million. Earnings were $40.34 million, an increase of 11.67%.